تاثیر دسفرال داخل وریدی در طول ترانسفیوژن خون در بیماران تالاسمی ماژور

عنوان انگليسی

The effect of intravenous Deferoxamine during blood transfusion time in thalassemia major patients

خلاصه انگلیسی

CONTEXT AND OBJCTIVE: Subcutaneous Deferoxamine intolerance by patients and reject its use Cause to iron overload and its complications. So, uses other methods with easier tolerate and reduce Deferoxamine consumption is necessary. One of these methods is concomitant use of intravenous Deferoxamine and blood transfusion which was investigated in this study. DESIGN AND SETTING: Semi-experimental study at the BU-Ali hospital in Ardabil University of medical science in North West of Iran. METHODS: in a Semi-experimental study, thirty four patients with �-thalassemia major who treated with monthly blood transfusion were randomly selected and followed for nine month. The mean of serum ferritin levels, subcutaneous Deferoxamine and Defripron uses rate in first three mount was considered as the baseline. Then at six months, the patients received intravenous Deferoxamine contaminant with their routine monthly blood transfusion and their chelators. After six mount the mean of ferritin, subcutaneous Deferoxamine and Defripron were checked again in the first and second three mounts compare with baseline. Data analyzed using statistical methods in SPSS.18 software. RESULTS: There were 15 men and 19 women of mean age 20.1±5.7years (range 7-28). The subcutaneous Deferoxamine and Defripron uses rate and ferritin level has been decreased in six mount compare to baseline. CONCLUSSION: Simultaneous intravenous Deferoxamine with routine monthly blood transfusion in beta thalassemia major due to decrease of ferritin level and subcutaneous deferoxamine and Defripron need without any increasing in complications.

Document Downloads